Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of GSK5764227 plus standard of care or other agents in advanced solid tumors
2025-522274-37-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of risvutatug rezetecan in colorectal cancer (CRC), metastatic colorectal adenocarcinoma (mCRC) and castration-resistant prostate cancer (CRPC) (2 cohorts), sponsored by GSK. Primary endpoint: Incidence and severity of adverse events and safety parameters. Planned start Nov 2025; status: authorised.
02
Drugs
risvutatug rezetecan
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2025-522274-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522274-37-00.